Sun Pharma Advanced Research Company (SPARC) shares plummeted nearly 20% after its psoriasis drug, SCD-044, failed to meet primary endpoints in Phase 2 trials.

Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India’s largest pharmaceutical firm Sun Pharma, fell 19 per cent to Rs 158 each after unsatisfactory Phase 2 trial ...

After the Astros’ bullpen imploded twice in the Rays’ series at Daikin Park, you can be excused if you are wary when the ...

Synchrony Financial remains profitable and resilient, supported by a strong capital buffer and prudent balance sheet ...